Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Pogled internista onkologa na sistemsko zdravljenje raka požiralnika
Avtorji:Reberšek, Martina (Avtor)
Mesti, Tanja (Avtor)
Boc, Marko (Avtor)
Jezik:Slovenski jezik
Tipologija:1.08 - Objavljeni znanstveni prispevek na konferenci
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Ključne besede:onkologija, rak požiralnika, sistemsko zdravljenje, rak prebavil
Leto izida:2014
UDK:616.3-006
ISSN pri članku:1408-1741
OceCobissID:1807227 Povezava se odpre v novem oknu
URN:URN:NBN:SI:doc-H68I2RZN
COBISS_ID:1808507 Povezava se odpre v novem oknu
Število ogledov:1303
Število prenosov:325
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (377,91 KB)
 
Nadgradivo:Šola: tumorji prebavil II, Ljubljana, 15. 11. 2013
Onkološki inštitut
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:by Authors
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:31.08.2018

Sekundarni jezik

Jezik:Angleški jezik
Naslov:[Treatment of oesophageal cancer from the medical oncologists' point of view]
Povzetek:The incidence of carcinoma of the oesophagus in Slovenia is small and has not changed in years. The prognosis of patients with metastatic carcinoma of the oesophagus is poor, with less than 10% 5-year survival. In the early stages of the disease, we recommend surgical treatment in combination with neoadjuvant chemoradiation for squamous cell carcinoma or perioperative systemic chemotherapy for adenocarcinoma of the gastroesophageal junction. In locoregionally advanced carcinoma, we recommend neoadjuvant chemoradiation. In the case of cervical carcinoma of the oesophagus or in high-risk patients not fit for surgery, we recommend definitive chemoradiation. The most optimal systemic therapy for metastatic disease is selected based on the general state of the patient, his concurrent diseases, the expected toxicity of systemic therapy, and HER2 status in patients with adenocarcinoma. For first-line treatment, we recommend doublet chemotherapy, mainly due to a better toxicity profile. In the case of HER2-positive adenocarcinoma, doublet may be combined with trastuzumab. In patients who are in good general condition, we can try with a combination of three cytostatics. For patients in poor general condition, only palliative supportive care is recommended, since the benefit of such treatment outweighs the potential treatment complications. We are eagerly awaiting the results of the ongoing clinical trials of new combinations of cytostatics and targeted drugs, hoping for more effective combinations of drugs that would enable us to treat patients with metastatic carcinoma of the oesophagus and gastroesophageal junction more effectively

Arhiv

niGradiv

Nazaj